Carbogen Amcis, a subsidiary of Dishman Carbogen Amcis specializing in pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing, has secured a strategic co-investment exceeding CHF 25 million with a long-standing Japanese customer to expand manufacturing capabilities at two Swiss facilities. The investment specifically targets increased production capacity for drug linkers used in commercial antibody-drug conjugates (ADCs).
Facility Expansion Details
The co-investment will fund significant equipment and infrastructure enhancements at both the Aarau and Neuland sites in Switzerland. At the Aarau facility, the company plans to install 850-litre reactors and 0.4 m² agitated filter dryers with supporting equipment, with completion expected by the first quarter of 2027. The Neuland site will receive similar upgrades, including 850-litre reactors and 0.4 m² agitated filter dryers with auxiliary systems, anticipated to be operational by the third quarter of 2027.
Strategic Partnership Continuation
This expansion builds upon a previous joint funding agreement established in April 2021 between Carbogen Amcis and the same Japanese customer for site extension development at the Bubendorf facility in Switzerland. The continued collaboration demonstrates the strength of the long-term partnership and shared commitment to growth in the ADC manufacturing sector.
"This expansion demonstrates our ability to scale alongside our customers, responding to the increasing demand for complex and high-value compounds such as ADC drug linkers," said Stephan Fritschi, CEO at Carbogen Amcis. "We're proud to continue building on our strong trust and technical collaboration foundation."
Manufacturing Capabilities Enhancement
Carbogen Amcis is recognized for its expertise in handling highly potent compounds, providing comprehensive support from process development through commercial supply. The new investments will strengthen the company's infrastructure to deliver high-quality manufacturing services compliant with current Good Manufacturing Practice (cGMP) standards and global regulatory expectations.
Carl Baker, Vice President Business Unit Drug Substance, emphasized the operational benefits: "By investing in both Aarau and Neuland, we're ensuring that our infrastructure keeps pace with our customers' ambitions. These upgrades will allow us to seamlessly manage increased volumes while maintaining the operational excellence and containment controls required for highly potent APIs and advanced therapies."
Global Manufacturing Network
With manufacturing facilities spanning Switzerland, France, the United Kingdom, the Netherlands, and China, Carbogen Amcis continues to expand its global footprint while delivering integrated Contract Development and Manufacturing Organization (CDMO) solutions to pharmaceutical and biopharmaceutical companies worldwide. The Swiss facility expansions represent a significant investment in meeting the growing demand for ADC therapeutics and other complex pharmaceutical compounds.
